問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
楊景堯
下載
2018-12-01 - 2024-06-21
Condition/Disease
NSCLC
Test Drug
Durvalumab
Participate Sites9Sites
Recruiting8Sites
Division of Thoracic Medicine
Division of Hematology & Oncology
2023-07-07 - 2026-07-31
Non-Small Cell Lung Cancer、 Head and Neck Squamous Cell Carcinoma
ABBV-514ABBV-181 (Budigalimab)
Participate Sites5Sites
Recruiting5Sites
2021-05-01 - 2024-12-31
Not yet recruiting1Sites
Recruiting4Sites
2022-08-01 - 2027-12-31
Participate Sites10Sites
Recruiting10Sites
2024-04-30 - 2027-04-30
Participate Sites3Sites
Recruiting3Sites
2015-12-10 - 2019-12-31
NON-SMALL CELL LUNG CANCER WHO HAVE BRAIN METASTASES
(1)Avastin; (2) Erlotinib
2019-04-01 - 2022-12-31
Participate Sites8Sites
Recruiting1Sites
Terminated7Sites
non-squamous non-small cell lung cancer
Durvalumab、Tremelimumab
Division of General Internal Medicine
2020-05-01 - 2025-05-31
A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
TAK-788 (AP32788)
Recruiting9Sites
2022-10-01 - 2024-12-12
全部
